Streetbeat News

Products Services

CVX

Chevron Pipe Line Company, a Chevron Corp subsidiary, and American Aerospace Technologies have received a unique FAA waiver to fly unmanned aircraft for surveillance in the San Joaquin Valley. This AiRanger UAS will enhance monitoring of Chevron's pipeline and production facilities.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 10:15 am

MNKD

MannKind Corporation announced that the FDA has granted Fast Track Designation for its Clofazimine Inhalation Suspension (MNKD-101) aimed at treating Nontuberculous Mycobacterial Lung Disease. This designation is expected to expedite the development and review process for MNKD-101, potentially bringing this new treatment option to patients sooner.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 10:10 am

ADCT

ADC Therapeutics SA announced initial data from a Phase 2 trial of ZYNLONTA showing a high response rate in patients with relapsed/refractory marginal zone lymphoma.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 10:04 am

WYNN

Wynn Resorts, Limited has unveiled new images of Wynn Al Marjan Island, a luxury resort under construction in Ras Al Khaimah, United Arab Emirates.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 8:01 am

GOOGL

META

Daniel McKinnon, an ex-product manager at both Meta Platforms Inc. (META) and Alphabet Inc. (GOOGL/GOOG), shared insights on work-life balance, compensation, and career progression at the two companies. McKinnon, who returned to Meta in February to work on Ray-Ban AI glasses, highlighted Meta's growth opportunities at the expense of stress, while Google offers better work-life balance and job security. Differences in compensation, project opportunities, and company culture were also discussed. Meta's Q1 revenue was $36.45 billion, up 27% YOY, while Alphabet's Q1 revenue increased by 15% YOY to $80.539 billion.

Portfolio Pulse from Ananya Gairola

May 06, 2024 | 7:52 am

MNMD

MindMed unveiled Phase 2b data of MM120 for Generalized Anxiety Disorder at the APA Annual Meeting, showing significant clinical benefits over placebo. The drug achieved a 65% clinical response rate and a 48% remission rate at 12 weeks. Additionally, MindMed presented two new studies on the burden of GAD in the US.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 7:47 am

URGN

UroGen Pharma Ltd. announced results from the ATLAS trial, showing that UGN-102 demonstrates sustained response rates in both new and recurrent bladder cancer patients at 12 months. The study focused on low-grade intermediate-risk non-muscle invasive bladder cancer patients treated with UGN-102, with or without subsequent TURBT.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 7:42 am

BMRN

BioMarin presented new data on VOXZOGO for treating multiple growth-related conditions in children at the PES Annual Meeting. Phase 2 and Phase 3 studies showed positive results in children with Noonan Syndrome, Idiopathic Short Stature, and Achondroplasia, indicating notable growth velocity increases.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 7:39 am

GEHC

GE HealthCare has introduced the SIGNA MAGNUS, a head-only magnetic resonance scanner aimed at advancing neuroscience research. The device, which is pending FDA 510(k) approval, represents a significant improvement over traditional whole-body MR systems, particularly in the fields of neurology, oncology, and psychiatry.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 7:25 am

LTRN

Lantern Pharma Inc. (LTRN) has announced a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of the drug candidate XCE853, a protein disulfide isomerase inhibitor aimed at treating various cancer indications. This collaboration will utilize Lantern's RADR AI platform to identify biomarkers and efficacy-associated signatures for XCE853, potentially guiding future clinical development and patient selection.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 7:00 am